Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Arcutis Biotherapeutics Inc shares valued at $156,383 were sold by Welgus Howard G. on Sep 02 ’25. At $15.64 per share, Welgus Howard G. sold 10,000 shares. The insider’s holdings dropped to 100,206 shares worth approximately $1.62 million following the completion of this transaction.
Also, Matsuda Masaru purchased 36,130 shares, netting a total of over 583,716 in proceeds.
Before that, Welgus Howard G. had added 10,000 shares to its account. In a trade valued at $156,083, the Director bought Arcutis Biotherapeutics Inc shares for $15.61 each.
As published in their initiating research note from Goldman on July 25, 2025, Arcutis Biotherapeutics Inc [ARQT] has been a Neutral and the price target has been revised to $18. Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in late December. As of August 28, 2024, Jefferies has initiated its “Buy” rating for ARQT. Earlier on January 03, 2024, Mizuho upgraded its rating. Their new recommendation was “a Buy” for ARQT stock which previously was a “a Neutral”.
Analyzing ARQT Stock Performance
On last trading session, Arcutis Biotherapeutics Inc [NASDAQ: ARQT] rose 1.69% to $16.21. The stock’s lowest price that day was $15.93, but it reached a high of $16.55 in the same session. During the last five days, there has been a surge of approximately 3.58%. Over the course of the year, Arcutis Biotherapeutics Inc shares have jumped approximately 48.99%. Shares of the company reached a 52-week high of $17.75 on 03/25/25 and a 52-week low of $11.13 on 02/11/25.
Support And Resistance Levels for Arcutis Biotherapeutics Inc (ARQT)
According to the 24-hour chart, there is a support level at 15.91, which, if violated, would cause prices to drop to 15.61. In the upper region, resistance lies at 16.53. The next price resistance is at 16.85. RSI (Relative Strength Index) is 58.54 on the 14-day chart, showing neutral technical sentiment.
Is Arcutis Biotherapeutics Inc subject to short interest?
Stocks of Arcutis Biotherapeutics Inc saw a sharp rise in short interest on 2025-08-15 jumping by 1.14 million shares to 18.4 million. Data from Yahoo Finance shows that the short interest on 2025-07-15 was 17.27 million shares. A jump of 6.19% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 10.49 of the overall float, the days-to-cover ratio (short ratio) jumped to 10.49.
Which companies own the most shares of Arcutis Biotherapeutics Inc (ARQT)?
In terms of Arcutis Biotherapeutics Inc share price expectations, FactSet research, analysts set an average price target of 19 in the next 12 months, up nearly 19.2% from the previous closing price of $15.94. Analysts anticipate Arcutis Biotherapeutics Inc stock to reach 19 by 2025, with the lowest price target being 19. In spite of this, 3 analysts ranked Arcutis Biotherapeutics Inc stock as Buy at the end of 2025. On October 26, 2023, Mizuho assigned a price target of “a Neutral” to the stock and downgraded coverage with a $4.
